AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schouten, M. A.
Right arrow Articles by The European VRE Study Group,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schouten, M. A.
Right arrow Articles by The European VRE Study Group,

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 1999, p. 2542-2546, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Antimicrobial Susceptibility Patterns of Enterococci Causing Infections in Europe

M. A. Schouten, A. Voss, J. A. A. Hoogkamp-Korstanje,* and The European VRE Study Groupdagger

University Hospital St. Radboud, Department of Medical Microbiology, 6500 HB Nijmegen, The Netherlands

Received 2 February 1999/Returned for modification 12 April 1999/Accepted 29 July 1999

In vitro susceptibilities of 4,208 enterococci (83% Enterococcus faecalis isolates, 13.6% Enterococcus faecium isolates, and 3.4% isolates of other species) from patients in 27 European countries towards 16 antibiotics were determined. High-level resistance to gentamicin varied by country (range, 1 to 49%; mean, 22.6% ± 12.3%) and per species (19.7% E. faecalis isolates, 13.6% E. faecium isolates, 3.4% by other species). Vancomycin resistance was detected in 0.06% E. faecalis, 3.8% E. faecium, and 19.1% isolates of other species. All enterococci were susceptible to LY 333328 and everninomicin, and 25% of E. faecalis isolates and 85% of other enterococci were susceptible to quinupristin-dalfopristin. The MIC of moxifloxacin and trovafloxacin for ciprofloxacin-susceptible E. faecalis at which 90% of the isolates were inhibited was 0.25 to 0.5 µg/ml.

* Corresponding author. Mailing address: University Hospital St. Radboud, Department of Medical Microbiology, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Phone: 30-24-3614356. Fax: 30-24-354 0216. E-mail: j.hoogkamp{at}mmb.azn.nl.

dagger Members of the European VRE Study Group are as follows: Austria, C. Jebelean, H. Mittermayer, and M. Rotter; Belgium, M. J. Struelens; Bulgaria, E. E. Keuleyan; Croatia, A. Boras; Czechoslovakia, J. Schindler; Denmark, A. Bremmelgaard, J. Renneberg, N. Frimodt-Moeller, and A. Lester; Finland, O. O. Liimatainen and J. Vuopio-Varkila; France, A. Andremont, C. Muller-Serleys, J. Etienne, and J. Raymond; Germany, L. Bader, J. Heesemann, R. Luetticken, R. R. Reinert, G. Peters, R. Gross, and P. M. Shah; Greece, G. Syrogiannopoulos and O. Vavatsi-Manou; Hungary, A. Marton and E. Nagy; Israel, C. Block and P. Yagupsky; Italy, G. A. Botta, G. Marchiaro, and S. Stefani; Latvia, D. Gardovska and L. Drukalska; Lithuania, V. Usonis; The Netherlands, H. P. Endtz, J. G. M. Koeleman, and J. F. G. M. Meis; Norway, A. Sundsfjord; Poland, M. Basta, P. B. Heczko, and E. Torbicka; Portugal, J. Melo-Cristino; Russia, I. A. Popova; Slovak Republic, V. Krcmercy, Jr.; Slovenia, M. Gubina; Spain, F. Asensi-Botet, C. Riestra, J. R. Cervilla, A. Trilla, and J. Villa; Sweden, L. G. Burman, M. H. Laurel, and M. Rylander; Switzerland, R. Frei; Turkey, G. Kanra; United Kingdom, P. R. Chadwick, E. H. Price, and H. Holzel.

Antimicrobial Agents and Chemotherapy, October 1999, p. 2542-2546, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1999 by the American Society for Microbiology. All rights reserved.